Pancreatic cancer is estimated to be the third leading cause of cancer-related mortality in the United States (US).^1,2 As has been the case for many years, the projected number of deaths in 2019 (45,750) is expected to nearly equal the number of new cases (56,770).^1,2 While the 5-year survival rate for all stages combined is approximately 9% (lowest among all cancers), more than half of all patients diagnosed with pancreatic cancer present with metastatic disease, which carries a 5-year survival rate of approximately 3%.^1,2

中文翻译：

---

白蛋白结合型紫杉醇加吉西他滨与 FOLFIRINOX 在晚期胰腺癌中的真实疗效比较：系统评价

据估计，胰腺癌是美国 (US) 癌症相关死亡的第三大原因。^1,2与多年来的情况一样，2019 年的预计死亡人数（45,750 例）预计几乎等于新病例数（56,770 例）。^1,2虽然所有阶段的 5 年生存率合计约为 9%（所有癌症中最低），但所有诊断为胰腺癌的患者中超过一半存在转移性疾病，其 5 年生存率约为3%。^1,2